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(23%). Over the two study periods, a smaller proportion of patients on bosentan than on
placebo required epoprostenol therapy (2.8% versus 4.3%), additional therapy for PAH
(28.6% versus 38.5%), or hospitalization (4.2% versus 13.0% for PAH-related and 16.0%
versus 23.2% for all causes of hospitalization).
Conclusion: The benefit achieved in exercise capacity, dyspnea, and reduced need for
additional therapy or hospitalization demonstrated in the initial 16-week BREATHE-1
study appears to be sustained when patients are followed for 28 weeks.
5:15 p.m.
825-6 Long-Term Secondary Prevention With Folic Acid: No 
Effects on Clinical Outcomes (the GOES Extension 
Study)
A. Liem, G. H. Reynierse-Buitenwerf, A. H. Zwinderman, J. W. Jukema, D. J. van 
Veldhuisen, Oosterschelde Hospital, Goes, The Netherlands
Purpose: Folic acid has favourable effects on vascular endothelium and lowers plasma
homocysteine levels. In addition, homocysteine appears to be an independent risk factor
for atherosclerotic disease. However, the value of folic acid in secondary prevention had
seldom been tested. Two yr folic acid treatment in the randomized GOES study showed
no reduction in clinical endpoints despite a 18% homocysteine reduction in patients on
folic acid. Suggested was that the follow up could have been too short, therefore the
study was extended with another 18 months Tx. Here we report results of the extended
Goes trial, an open-label trial with folic acid 0.5 mg per day in a patient population with
stable coronary artery disease (CAD).
Methods: 593 Patients were included in this study; 300 were randomized to folic acid and
293 served as controls. Mean follow-up time was 42 months. At baseline all patients had
been on statin therapy for a mean of 3.2 years.
Results: In patients treated with folic acid plasma homocysteine levels decreased with
18% from 12.0 ± 4.8 to 9.4 ± 3.5 µmol/L, while these levels remained unaffected in the
control group (p <0.001 between groups). The primary endpoint (all-cause mortality and
a composite of vascular events) was encountered in 75 (25.0%) patients in the folic acid
group and in 75 (25.6%) patients in the control group (RR 0.98; p=NS). Also in the quar-
tile of patients with the highest baseline homocysteine levels (>13.7 micromol/L) no salu-
tary effects of folic acid Tx could be demonstrated. In a multifactorial survival model with
adjustments for clinical factors the most predictive laboratory parameters were, in order
of significance, levels of creatinine clearance, and homocysteine.
Conclusions: Within 3.5 years folic acid does not seem to reduce clinical endpoints in
patients with stable CAD while on statin treatment. Homocysteine might therefore merely
be a marker of disease than a causal risk factor. Thus, until more trials will become avail-
able, low dose folic acid supplementation should be treated with reservation.
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Atherosclerotic Plaque, Inflammation, 
and Oxidative Stress: Clinical Studies
Tuesday, March 09, 2004, 8:30 a.m.-10:00 a.m.
Morial Convention Center, Room 265
8:30 a.m.
831-1 Ruptured Diabetic Atherosclerotic Plaques Have More 
Inflammation and Neovascularization Than Ruptured 
Plaques From Patients Without Diabetes
K. Raman Purushothaman, William N. O'Connor, Dario Echeverri, Chikezie Amadi, Juan 
J. Badimon, Valentin Fuster, Pedro R. Moreno, Mount Sinai Medical Center, New York, 
NY, University of Kentucky, Lexington, KY
Background: Plaque rupture may be asymptomatic or precipitate acute thrombotic
events, and patients with diabetes mellitus (DM) are at higher risk for acute events than
patients without DM. To evaluate if this difference is related to plaque composition, we
quantified inflammation and neovascularization in ruptured aortic plaques from patients
with/without DM.
Methods: Neovessels and macrophages/T cells were identified by CD34 (blue) and
CD68/CD3 (red) bicolor immunohistochemistry (Figure) in 41 DM ruptured and com-
pared to 34 non-DM ruptured plaques.
Results: See table.
Conclusion: Ruptured plaques from DM have increased inflammation and neovascular-
ization supporting plaque composition as a contributor for the increased incidence of
atherothrombotic complications among DM population.
8:45 a.m.
831-2 Coronary Lumen Change Is Determined Primarily by 
Adventitial Remodeling Rather Than Plaque Change 
During Therapy
David T. Linker, B. Greg Brown, University of Washington, Seattle, WA
Background: Remodeling of coronary arteries has been demonstrated during plaque
regression, but the contribution to lumen change is unclear.
Methods: Intracoronary ultrasound automated pull-backs were recorded on S-VHS tape
both before and after twelve months of lipid-lowering therapy in a target coronary artery
in 18 subjects with known coronary artery disease. The pullbacks were digitized and cal-
ibrated, and identical segments with plaque in the target artery were identified on the pre-
and post-therapy images. The lumen and adventitia-media borders were manually traced
on all images in the segment that allowed image interpretation, with the longitudinal posi-
tion noted. The plaque and adventitial volumes were calculated by a numerical integra-
tion of the area over the longitudinal length. The mean plaque adventitial, and lumen
areas in sq. mm were calculated based on plaque and adventitial volume and segment
length.
Results: The change in mean lumen area was poorly correlated with the change in
mean plaque area (R = 0.256, p = 0.306). Lumen area change was strongly correlated
with adventitial area change (R = 0.903, p <0.001, see figure below) The relationship was
Change in mean lumen area = 0.712 x Change in mean adventitial area + 0.347 mm2.
Conclusions: The changes in lumen area after one year of lipid-lowering therapy are
better correlated with adventitial change than with plaque change, indicating that arterial
remodeling is an important determinant of lumen change.
9:00 a.m.
831-3 Circulating Endothelial Progenitor Cells Predict 
Coronary Artery Disease Severity
Geoffrey A. Kunz, Grace Liang, Florim Cuculoski, David Gregg, Korkut Vata, Linda Shaw, 
Pascal Goldschmidt-Clermont, Chunming Dong, Doris Taylor, Eric Peterson, Duke 
University, Durham, NC
Background: Circulating endothelial progenitor cell (EPC) counts are hypothesized to
play an important role in preventing atherosclerosis. EPC counts have been found to be
inversely related to traditional coronary artery disease (CAD) risk factors, yet their asso-
ciation to CAD severity remains unknown.
Methods: We measured EPC counts by quantitative cell culture in 122 patients undergo-
ing diagnostic cardiac catheterization. The association between patients’ EPC count and
the presence of multi-vessel CAD and of traditional cardiac risk factors was assessed
using logistic regression analysis. Results: The median age of the study population was
Neovessel Unit (Total 
Count)
Diabetic Ruptured 
Plaques (n=41)
Non-Diabetic Ruptured 
Plaques (n=34)
P Value
Neovessels in the 
outer media
173 ± 61 104 ± 42 0.0001
Neovessels in the 
inner media
124 ± 52 48 ± 24 0.0001
Neovessels in the 
intima
27 ± 20 13 ± 10 0.0001
Inflammation score 
(0-2)
1.8 ± 0.5 1.5 ± 0.5 0.0001
